Summary: Bavarian Nordic increases its share capital by nominally DKK 13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct placement to Johnson & Johnson Development Corporation ("JJDC") in connection with the license and supply agreement for the Company's MVA-BN® vector in respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson. KVISTGAARD, Denmark, October 29, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces the completion of the direct placement of 1,331,984 new shares of nominal value DKK 10 each (corresponding to approximately 4.85% of the Company's share capital after completion of the direct placement) in Bavarian Nordic at a subscription price of DKK 188.4407 per new share to JJDC, raising gross proceeds to Bavarian Nordic of DKK 250,999,997.35. The direct placement, which is made in connection with the license and supply agreement for the Company's MVA-BN® vector in respect of Ebola between Bavarian Nordic and Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson, was originally announced on 22 October 2014 (Company Announcements Nos. 22 and 23). Bavarian Nordic's share capital will amount to DKK 274,448,470 after registration of the capital increase with the Danish Business Authority. Bavarian Nordic's new articles of association will be published separately and will be available at Bavarian Nordic's website, www.bavarian-nordic.com. It is expected that the new shares will be admitted to trading and official listing on Nasdaq Copenhagen on 31 October 2014. Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. About MVA-BN® MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology of Bavarian Nordic. MVA-BN is a robust and adaptable platform suitable for addressing a wide variety of infectious diseases, including biological threats. In addition to developing MVA-BN as a safer smallpox vaccine (approved in the EU and Canada) essential to protecting the immune-compromised population, Bavarian Nordic has conducted more than a dozen preclinical and clinical studies of recombinant MVA-BN-based vaccines. More than 7,500 individuals, nearly 1,000 of whom are immunocompromised, have been vaccinated with MVA-BN-based vaccines, showing the platform displays high immunogenicity and a favorable safety profile. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1866653]
Capital Increase in Bavarian Nordic A/S as a Result of
Top 10 Most Recent News Articles
Yatsen’s November 25 Report Is the Real Beauty Test
Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...
Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas
China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...
Continue Reading
Vertex Extends Genomics Pact With $220M in Potential
Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...
Continue Reading
Exiger's CEO Honored for Military Support Excellence
Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...
Continue Reading
Photocure Opens a New Access Route for Hexvix Patients
Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...
Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off
Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...
Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test
Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...
Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market
A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...
Continue Reading
Diwali at Heritage Shows the Real Estate Community Test
Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...
Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices
Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...
Continue ReadingTop 5 Most Recently Viewed Articles
GRAX Honored as Cybersecurity Innovator by BostInno Awards
GRAX Recognized as a Leader in Cybersecurity GRAX, Inc., well-known for its innovation in Salesforce data management and protection, has recently earned an esteemed recognition as a 2024 Fire honoree in cybersecurity from BostInno. This award celebrates companies that are driving innovation in the Boston area, emphasizing GRAX's role as a pioneer in data security....
Continue Reading
i2Cool and Marubeni Join Forces for Revolutionary Cooling Tech
i2Cool and Marubeni Forge Strategic Partnership i2Cool, a pioneering company in the realm of electricity-free cooling technology, has established a significant global partnership with Marubeni, a prominent trading company from Japan. This collaboration is designed to facilitate the widespread adoption of electricity-free cooling technologies, concentrating particularly on...
Continue Reading
Jasper Therapeutics Upcoming Investor Conferencs - September 2024
Jasper Therapeutics to Showcase Innovations at September Events Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic...
Continue Reading
Tech Sector Thrives as Meta Drives Nasdaq-100 to New Heights
Tech Sector Soars with New Nasdaq-100 Records The Nasdaq-100 has reached an unprecedented high of 22,191.37, highlighting the unyielding strength of tech stocks. The renowned Invesco QQQ Trust (NASDAQ: QQQ) has also achieved a 52-week peak, reaching $540, demonstrating the energetic rally across the technology market. Meta Platforms Inc's Remarkable Performance Meta...
Continue Reading
Millicom Advances Infrastructure Sale and Special Dividend Plans
Millicom Announces Infrastructure Deal Progress Millicom International Cellular S.A. (NASDAQ: TIGO) has made significant strides in its transaction with SBA Communications. The company recently revealed the partial closing of its sale involving LATI International S.A., the holding company for its mobile passive infrastructure assets in Central America. This deal has...
Continue Reading